Danaher Corp (NYSE: DHR) is a life sciences and diagnostics instruments company whose 10-K filed February 24, 2026 references operating segments including Life Sciences and genomics consumables businesses. The filing does not provide sufficient segment revenue breakdowns, customer concentration data, geographic mix, competitor names, founding year, CEO tenure, or core revenue model details to construct a fully sourced canonical description within these excerpts. The filing does disclose a $432 million pretax noncash impairment charge ($328 million after-tax) for the year ended December 31, 2025, related to a trade name in the Life Sciences operating segment, connected to a decision to reorganize and integrate certain genomics consumables businesses. The filing also references a reporting unit with a carrying value of approximately $10.1 billion as of the FY2025 goodwill impairment test. Pension contributions in FY2025 totaled $9 million to U.S. defined benefit plans and $41 million to non-U.S. defined benefit plans.
Genomics consumables (Life Sciences operating segment, FY2025); trade names valued via relief-from-royalty method per FY2025 10-K filing.
U.S. and non-U.S. operations referenced via defined benefit pension plans (FY2025 10-K).
Loading...